Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MD2L
|
|||
| Former ID |
DAP001516
|
|||
| Drug Name |
Rufinamide
|
|||
| Synonyms |
106308-44-5; Inovelon; Banzel; 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide; CGP-33101; Cgp 33101; Xilep; 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide; RUF-331; UNII-WFW942PR79; RUF 331; 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide; WFW942PR79; C10H8F2N4O; E 2080; POGQSBRIGCQNEG-UHFFFAOYSA-N; 1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-; NCGC00165883-02; E2080; DSSTox_CID_26506; DSSTox_RID_81675; DSSTox_GSID_46506; Banzel; Banzel, Rufinamide; E-2080; SYN-111; Rufinamide (USAN/INN); Inovelon/Banzel
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Epilepsy [ICD-11: 8A60-8A68] | Approved (orphan drug) | [1], [2] | |
| Pediatric lennox-gastaut syndrome [ICD-11: 8A62.1; ICD-9: 345] | Approved | [3] | ||
| Seizure disorder [ICD-11: 8A6Z] | Approved | [1], [4], [5] | ||
| Company |
Eisai
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H8F2N4O
|
|||
| Canonical SMILES |
C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F
|
|||
| InChI |
1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
|
|||
| InChIKey |
POGQSBRIGCQNEG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 106308-44-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10242268, 12014051, 15121846, 24724595, 29217641, 29308110, 47207436, 50111716, 56320687, 56323499, 57342925, 58107211, 80334982, 90341717, 90342554, 92718980, 93309661, 99437055, 103771489, 104369993, 109693097, 118317931, 121361738, 124757121, 124772079, 124800269, 125163925, 125337281, 126600262, 126621181, 126651848, 126667055, 128944616, 131293789, 134338700, 134340299, 135085479, 135653558, 135698201, 136343339, 137027833, 137255007, 142190226, 143493273, 144205820, 152241718, 162037521, 162184408, 163124160, 163564750
|
|||
| ChEBI ID |
CHEBI:134966
|
|||
| ADReCS Drug ID | BADD_D01977 | |||
| SuperDrug ATC ID |
N03AF03
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium channel unspecific (NaC) | Target Info | Blocker | [6] |
| KEGG Pathway | Dopaminergic synapse | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7470). | |||
| REF 2 | Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39. | |||
| REF 3 | Clinical pipeline report, company report or official report of Eisai. | |||
| REF 4 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | |||
| REF 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 6 | Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.